Otsuka Pharmaceutical had received a patent for delamanid in India in 2011 but had not launched it.MDR TB is on the rise in India which, together with China and Russia, accounts for over half of these cases worldwide, according to a recent study published in The Lancet, a medical journal. India’s drug regulator has already granted Mylan’s subsidiary approval for delamanid, the company said in a global release. The drug was discovered and developed by Otsuka.At least 400 patients in India will likely have access to delamanid as part of the government’s conditional access programme in the next six months, a senior health ministry official told ET. Mylan will provide these 400 courses for free, the official said. Otsuka’s patent for delamanid is valid in India until 2022.

Source: Economic Times August 25, 2017 17:59 UTC